References
- CoxMERowellJCorsinoLGreenJBDipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacyDrug, Healthcare and Patient Safety20102719
- HeiseTGraefe-ModyEUHüttnerSRingATrommeshauserDDugiKAPharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patientsDiabetes Obes Metab200911878679419476474